Methodology
So you can judge how solid the ranking is, the calculation is laid open here. No statistical prediction model and no language model — a hand-curated database and a disclosed weighting by evidence grade (A 1.0 · B 0.8 · C 0.6 · D 0.4) that you can recompute here.
Where the numbers come from
Every effect row is entered by hand from the published literature, with range, latency, evidence grade and source. No entry is generated or estimated at runtime. Where a figure is uncertain, a weak evidence grade sits next to it, and where no curated figure exists yet, the entry is marked as an unconfirmed placeholder.
The catalogue in figures, counted from the same database this page serves.
- Markers
- 28
- Measures
- 42
- Effect rows
- 221
- Sources
- 225
Evidence grades
The evidence grade describes how well the effect on the lab value is established. It says nothing about whether your clinical outcome changes with it. That sits separately in the outcome column.
- Evidence grade A
- Several randomised trials or meta-analyses pointing the same way
- Evidence grade B
- Individual randomised trials or consistent observational data
- Evidence grade C
- Small or methodologically limited studies, result not settled
- Evidence grade D
- Mechanistic reasoning or expert opinion, little direct data
How the ordering works
For each measure, one row counts per marker you entered. The contribution grows with how far your value sits from the target range, with the point estimate against the largest known effect in the same unit, and with the evidence grade. Rows without a number keep a neutral size. Markers with no established treatment direction count with weight 0 and stay visible.
Evidence-grade weighting exactly as it stands in the code: A counts 1.0, B 0.8, C 0.5, D 0.3. The marker's urgency tier (1, 0.6, 0.3, 0.05) is applied as well. That lets you recompute any ordering here.
Big levers and small dials share one list. The order follows the evidence, not the category. A poor trade, where the cost sits on a more important marker, is shown in its own section.
Weight reduction drops out of the ranking when height and weight yield a BMI below 18.5. Without those figures the lever stays visible.
Whether an edge is benefit or cost follows from the effect direction and the marker's desirable direction. Markers without an established treatment direction (HDL, hs-CRP, homocysteine, vitamin D, total cholesterol) stay informational — never green progress. A row with direction none is a finding, not an empty cell.
Hidden raisers and prescription context explain a high value. They are for orientation, not lifestyle advice in the ranking.
Both sides stay on the card
The order follows benefit minus cost. On the card the two sides stay separate, rather than collapsing into one combined number. A poor trade goes in its own section. Whether an added purine load matters to you depends on your uric acid, your kidney function and your history of gout.
Food alternatives
The search compares curated foods in the same class using recorded nutrients per 100 g. Suggestions are not a diagnosis. Composition comes from the German Nutrient Database BLS 4.0; purines come from the free USDA/ODS-NIH purine database (which includes Kaneko 2014). Qualitative reasons such as live cultures or a preparation are editorial notes, not effect rows.
How the calculation runs technically
When the page loads, the server delivers the anonymous effect database. Your values stay in a variable in the browser and are combined with that database there. Without an account they never flow back into a request. With an account the browser stores the history as ciphertext; plaintext figures are not in the database. The values are also absent from the address bar.
What we count
There is no tracking and no cookie banner, because there is no reason for one. To see whether the entry point works, we count three events. All that is stored per event and day is one number: how often it happened.
- Form started: someone entered a value or had a report read in.
- PDF read: a report was parsed in the browser. The file itself never leaves your device.
- Result seen: the assessment was displayed.
No lab value, no marker, no IP address and no identifier goes into these counters. So that one visit does not count several times, the browser remembers the event for that tab. We cannot tell from this who you are or what your report says.
Markers and target ranges
The recorded target ranges with their source. Laboratory-specific reference ranges may differ; the range printed on your own report always takes precedence.
| Marker | Unit | Target range | Favourable direction | Source |
|---|---|---|---|---|
| Triglycerides | mg/dL / mmol/L | < 150 | lower | 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk |
| HDL cholesterol | mg/dL / mmol/L | > 40 | no established direction | 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 |
| Apolipoprotein B | mg/dL / g/L | < 100 | lower | 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk |
| LDL cholesterol | mg/dL / mmol/L | < 100 | lower | 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk |
| Fasting glucose | mg/dL / mmol/L | < 100 | lower | 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025 |
| HbA1c | % | < 5.7 | lower | 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026 |
| Fasting insulin | µIU/mL / pmol/L | < 10.0 | lower | Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in manUnconfirmed placeholder |
| HOMA-IRGlucose × Insulin ÷ 405 | index | — | lower | — |
| Ferritin | ng/mL / µg/L | 15–200 | in range | WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations |
| Uric acid | mg/dL / µmol/L | < 6.0 | lower | 2020 American College of Rheumatology Guideline for the Management of Gout |
| Creatinine | mg/dL / µmol/L | < 1.20 | lower | KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease |
| Cystatin C | mg/L | < 1.00 | lower | KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease |
| eGFR (creatinine) | mL/min | > 60 | higher | KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease |
| eGFR (cystatin C) | mL/min | > 60 | higher | KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease |
| egfr-discrepancy | % | -30–30 | in range | Discordance in Creatinine- and Cystatin C-Based eGFR and Clinical Outcomes: A Meta-Analysis |
| Alanine aminotransferase | U/L | < 33 | lower | ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries |
| Aspartate aminotransferase | U/L | < 40 | lower | ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries |
| Gamma-glutamyltransferase | U/L | < 40 | lower | Common reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) in serum: results from an IFCC multicenter study |
| Platelet count | 10⁹/L | 150–400 | in range | Age- and sex-based ranges of platelet count and cause-specific mortality risk in an adult general population: prospective findings from the Moli-sani study |
| fib-4 | index | < 1.30 | lower | AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease |
| Homocysteine | µmol/L | < 15.0 | no established direction | Hyperhomocysteinemia and Disease - Is 10 umol/L a Suitable New Threshold Limit? |
| high-sensitivity CRP | mg/L | < 2.0 | no established direction | 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 |
| 25-OH vitamin D | ng/mL / nmol/L | > 20 | no established direction | Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline |
| Systolic blood pressure | mmHg | < 130 | lower | 2024 ESC Guidelines for the management of elevated blood pressure and hypertension |
| Diastolic blood pressure | mmHg | < 80 | lower | 2025 AHA/ACC and multisociety Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults |
Limits
- All ranges come from group averages. Within a single study, individual responses run from far stronger to none at all.
- The ordering uses the point estimate in the marker's own unit. Where no number exists, the row stays visible and counts with a neutral size.
- Several measures do not add up cleanly in reality. We therefore show them individually and never as a sum.
- Medication, pre-existing conditions, pregnancy, thyroid function and alcohol consumption change the picture considerably and are not included here.
- A single lab value is a point in time with measurement scatter, not a state. Triglycerides in particular react strongly to the last meal.
What has changed
When we change something substantial in the database or in the presentation, it is listed here. Same log as on the home page.
2026-10
Ranking uses the literature point estimate. Rows without a settled size stay visible and do not count. HDL, hs-CRP, homocysteine and vitamin D stay blue, not as progress.
2026-09
Borderline badges removed. Study spans instead of point forecasts. Reporting without an account. FIB-4 and eGFR discrepancy taken out of the consumer product.
2026-08
Consolidated-3 import: lifestyle levers, hidden raisers and prescription context with sources.